18 August 2025 -  Iovance Biotherapeutics today announced Health Canada has issued a Notice of Compliance with Conditions for Amtagvi (lifileucel), a tumour-derived autologous T cell immunotherapy. 

Amtagvi is indicated for the treatment of adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy including a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor, and who have no satisfactory alternative treatment options.

Read Iovance Biotherapeutics press release